May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Ten-Year Estimated Progression Rates to Neovascular AMD and Central Geographic Atrophy From the Age-Related Eye Disease Study (AREDS)
Author Affiliations & Notes
  • E. Y. Chew
    Epidemiology & Clinical Research, National Eye Inst/NIH, Bethesda, Maryland
  • G. Cohen
    EMMES Corporation, Rockville, Maryland
  • T. Clemons
    EMMES Corporation, Rockville, Maryland
  • R. Milton
    EMMES Corporation, Rockville, Maryland
  • Age-Related Eye Disease Study Research Group
    Epidemiology & Clinical Research, National Eye Inst/NIH, Bethesda, Maryland
  • Footnotes
    Commercial Relationships  E.Y. Chew, None; G. Cohen, None; T. Clemons, None; R. Milton, None.
  • Footnotes
    Support  NEI Intramural Support and NEI/NIH Contract
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5065. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. Y. Chew, G. Cohen, T. Clemons, R. Milton, Age-Related Eye Disease Study Research Group; Ten-Year Estimated Progression Rates to Neovascular AMD and Central Geographic Atrophy From the Age-Related Eye Disease Study (AREDS). Invest. Ophthalmol. Vis. Sci. 2008;49(13):5065. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To provide estimated 10-year progression rates to neovascular AMD (NV AMD) and central geographic atrophy (CGA) using data from the Age-Related Eye Disease Study (AREDS).

 
Methods:
 

4642 participants enrolled in AREDS were classified by a reading center based on stereoscopic color fundus photographs taken at baseline, two years following enrollment, and annually thereafter. Cases of advanced AMD (AAMD) were identified by a history of photocoagulation for neovascularization or by photographic evidence of either central geographic atrophy or neovascular AMD. AREDS included a clinical trial with participants randomized to treatment with placebo, antioxidants, zinc, or a combination of antioxidants and zinc. Stratified proportional hazards models were used to estimate the probability of progression to NV AMD or CGA based on baseline drusen status. Covariates included age, gender, smoking status, and AREDS treatment.

 
Results:
 

Participants were followed for a median of 10.5 years. The estimated percent probability of NV AMD or CGA after 10 years of follow-up, by baseline drusen size and adjusted for covariates, is shown below.Estimated cumulative incidence rates for various covariate patterns, such as age, gender, smoking, will also be provided. For example, the probability of NV AMD for a non smoker male age 55-64 with AAMD in the fellow eye and randomized to placebo is 42.3% compared with 35.4% for a similar participant randomized to one of three active treatments.  

 
Clinical Trial:
 

www.clinicaltrials.gov NCT00000145

 
Keywords: age-related macular degeneration • antioxidants • drusen 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×